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We found that centrally administered prostaglandin (PG) E2 exhibited anxiolytic-like activity in the
elevated plus-maze and open ﬁeld test in mice. Agonists selective for EP1 and EP4 receptors, among
four receptor subtypes for PGE2, mimicked the anxiolytic-like activity of PGE2. The anxiolytic-like
activity of PGE2 was blocked by an EP1 or EP4 antagonist, as well as in EP4 but not EP1 knockout mice.
Central activation of either EP1 or EP4 receptors resulted in anxiolytic-like activity. The PGE2-
induced anxiolytic-like activity was inhibited by antagonists for serotonin 5-HT1A, dopamine D1
and GABAA receptors. Taken together, PGE2 exhibits anxiolytic-like activity via EP1 and EP4 receptors,
with downstream involvement of 5-HT1A, D1 and GABAA receptor systems.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Prostaglandin (PG) E2 is produced in the mammalian central
nervous system (CNS), and has a variety of central actions such
as in fever, pain generation, wakefulness and anorexia under both
physiological and pathophysiological conditions [1–5]. PGE2 exerts
its actions through four different types of G-protein-coupled se-
ven-transmembrane receptors, known as EP1, EP2, EP3 and EP4
[6,7]. Recently, functions of these receptor subtypes in the CNS
have been revealed using their highly selective ligands or knockout
mice. It was reported that EP4 receptor mediates wakefulness of
PGE2 [2]. We also demonstrated that central activation of EP4
receptor suppresses food intake and gastrointestinal motility [8].
Various neural responses are evoked by sickness. It was reported
that EP3 receptor mediates the febrile response induced by bacte-
rial endotoxin lipopolysaccharide (LPS), which mimics the condi-
tion of systemic sickness [3]. Both EP1 and EP3 receptor work
critically in activation of the hypothalamic–pituitary–adrenal
(HPA) axis after LPS administration [9].chemical Societies. Published by E
nata).Interestingly, psychological stress not related sickness also en-
hances PG production in the CNS [10,11]; however, the mechanism
underlying the emotional regulation of central PGs is largely un-
known. We have recently reported that PGD2, a structural isomer
of PGE2, has anxiolytic-like activity via DP1 receptor among two
receptor subtypes for PGD2 [12]. In this study, we focused on the
role of PGE2 in the emotional regulation, behavioral pharmacolog-
ically using highly selective ligands for receptor subtypes for PGE2
[13] as well as knockout mice. We also investigated the neuro-
transmitters associated with the anxiolytic-like activity induced
by central administration of PGE2.
2. Materials and methods
2.1. Materials
PGE2 was obtained from Nacalai Tesque Inc. (Kyoto, Japan). The
highly selective EP1 agonist (ONO-DI-004), EP2 agonist (ONO-AE1-
259-01), EP3 agonist (ONO-AE-248), EP4 agonist (ONO-AE1-329),
EP1 antagonist (ONO-8713) and EP4 antagonist (ONO-AE3-208)
were provided by Ono Pharmaceutical Co. Ltd. (Osaka, Japan).
WAY100135 dihydrochloride, a serotonin 5-HT1A receptor antago-
nist; R(+)-SCH-23390 hydrochloride, a dopamine D1 receptorlsevier B.V. All rights reserved.
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Fig. 1. Anxiolytic-like activity of PGE2 after central administration in the elevated
plus-maze (EPM) test in mice. PGE2 at a dose of 10–100 pmol/mouse was i.c.v.
administered 20 min before the test. The percentages of time (A) and visits (B) spent
in the open arms, and total visits (C) to both open and closed arms during the test
for 5 min were measured. Each value is expressed as the mean ± S.E.M. (n = 4–6).
⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, compared with the ACSF-treated control group.
2358 C. Suzuki et al. / FEBS Letters 585 (2011) 2357–2362antagonist; and ()-bicuculline, a c-amino butyric acid (GABA)A
receptor antagonist; were obtained from Tocris Bioscience (Bristol,
UK).
2.2. Animals
Four-week-old male ddY mice were obtained from SLC (Shi-
zuoka, Japan). We also used EP1- and EP4-knockout (KO) and their
wild-type mice as previously reported [9,14]. All animals were
housed in a temperature-controlled room (23 C) on a 12 h light–
dark cycle with lights on at 07:00. All animals had free access to
food pellets and water. All experiments were approved by the Kyo-
to University Ethics Committee for Animal Research Use. All ani-
mals were euthanized by an overdose of anesthesia drugs after
the experiment.
2.3. Intracerebroventricular (i.c.v.) administration
i.c.v. administration to mice weighing 20–24 g was performed
as described previously [15–17]. Brieﬂy, a 28-gauge stainless steel
needle attached to a 0.05-ml Hamilton syringe was inserted per-
pendicularly through the skull into the brain. The site of injection
was 2 mm from either side of the midline on a line drawn through
the anterior base of the ears (the lateral ventricle).
2.4. Elevated plus-maze test
Anxiolytic-like behavior was measured using the elevated plus-
maze (EPM) test, which was performed as described previously
[12,18–21]. Four arms (25 cm long  5 cm wide) were placed
50 cm above the ground. Two opposing arms were delimited by ac-
rylic vertical walls (15 cm high, closed arms), and two had unpro-
tected edges (open arms). A mouse was placed in the center of the
maze facing an open arm and observed for 5 min to measure the
cumulative time and frequency of entries into open and closed
arms. Arm entry was deﬁned as the entry of four paws into an
arm. Open-arm entry time (time spent in open arms) was ex-
pressed as a percentage of the total entry time (% of time), and
the number of open-arm entries was expressed as a percentage
of the total number of entries (% of visit). PGE2 or the EP1–EP4 ago-
nist was dissolved in dimethylsulfoxide (DMSO) and the solution
was diluted 20-fold with artiﬁcial cerebrospinal ﬂuid (ACSF:
138.9 mM NaCl, 3.4 mM KCl, 1.3 mM CaCl2, 4.0 mM NaHCO3,
0.6 mM NaH2PO4, 5.6 mM glucose, pH 7.4). Four microliters of
PGE2 or an EP agonist solution were co-administered with or with-
out an EP antagonist i.c.v. 20 min before the test. The antagonist of
5-HT1A, D1 or GABAA receptor (i.p.) or PGE2 (i.c.v.) was adminis-
tered 30 or 20 min, respectively, before the test. The total number
of visits to open and closed arms, and the cumulative time spent in
open and closed arms were measured on a monitor through a video
camera system. The data were checked by observers unaware of
the experimental groups. The EPM test was started at 11:00 am
during the light phase of the light/dark cycle.
2.5. Open ﬁeld test
The open-ﬁeld test was performed as previously described with
a slight modiﬁcation [21,22]. The apparatus consisted of a black
circular arena of 60 cm in diameter and a gray wall 50 cm tall. Four
microliters of PGE2, EP1 or EP4 agonist solution were administered
i.c.v. 20 min before the open ﬁeld test. Each mouse was placed in
the center of the circular arena and its movement monitored
through the video-tracking system Smart Junior (Panlab, S.L., Bar-
celona, Spain) for 5 min. The time spent in a circular area 12 cm
in diameter in the center of the arena was measured. The open-
ﬁeld test was started at 11:00 am.2.6. Statistical analysis
Values are expressed as the mean ± S.E.M. Statistical compari-
sons between groups were performed using a one-way analysis
of variance (ANOVA) followed by Fisher’s test or the unpaired Stu-
dent’s t-test. P values less than 0.05 were considered signiﬁcant.
3. Results
3.1. Centrally administered PGE2 has anxiolytic-like activity
We investigated the role of PGE2 in emotional regulation using
the elevated plus-maze and open ﬁeld tests. Centrally adminis-
tered PGE2 (10–100 pmol/mouse) dose-dependently increased per-
centages (%) of time and visits in open arms in the elevated plus-
maze test (Fig. 1). Total visits in both open and closed arms, which
indicate locomotor activity, did not change signiﬁcantly after the
i.c.v. administration of PGE2. One hundred pmol/mouse of PGE2
also increased % time spent in the center (12 cm) and the frequency
of rearing in the open ﬁeld test (Table 1). Thus we demonstrated
with two paradigms that centrally administered PGE2 exhibits anx-
iolytic-like activity in mice.
3.2. Activation of EP1/EP4 receptors exhibits anxiolytic-like activity
To investigate which receptor subtypes for PGE2 mediate the
anxiolytic-like activity of PGE2, we used highly selective agonists
for EP1–EP4 receptors. The EP1 and EP4 agonists at a dose of
100 pmol/mouse increased % of time and visits in open arms
(Fig. 2). The EP3 agonist seemed to slightly increase visits in open
arms; however, statistically signiﬁcant differences compared to
the ACSF-treated control group were not detected. Total visits to
the open and closed arms were not affected. The EP1 or EP4 agonist
(100 pmol/mouse) also increased % time spent in the center and
the frequency of rearing in the open ﬁeld test (Table 2). These
Table 1
Anxiolytic-like activity of PGE2 at a dose of 100 pmol/mouse after i.c.v. administration
in the open-ﬁeld test.
ACSF PGE2
% of time in center circle 0.467 ± 0.214 1.27 ± 0.129*
Frequency of rearing 33.6 ± 6.75 63.8 ± 3.92**
Results are expressed as the mean ± S.E.M. (n = 10).
* P < 0.05 compared with the ACSF-treated control group.
** P < 0.01 compared with the ACSF-treated control group.
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Fig. 2. Anxiolytic-like activity of a highly selective EP1, EP2, EP3 or EP4 receptor
agonist after central administration in the EPM test in mice. ONO-DI-004, ONO-
AE1-259-01, ONO-AE-248 or ONO-AE1-329, an agonist for the EP1, EP2, EP3 or EP4
receptor, respectively, which are receptor subtypes for PGE2, was i.c.v. administered
at a dose of 100 pmol/mouse 20 min before the test. Each value is expressed as the
mean ± S.E.M. (n = 4). ⁄P < 0.05, ⁄⁄P < 0.01, compared with each group.
Table 2
Anxiolytic-like activities of EP1and EP4 agonists at a dose of 100 pmol/mouse after
i.c.v. administration in open-ﬁeld test.
ACSF EP1 agonist EP4 agonist
% of time in center circle 0.683 ± 0.222 1.74 ± 0.189** 2.11 ± 0.367***
Frequency of rearing 31.4 ± 3.02 43.9 ± 3.48* 53.1 ± 5.65**
Results are expressed as the mean ± S.E.M. (n = 8–9).
* P < 0.05 compared with the ACSF-treated control group.
** P < 0.01 compared with the ACSF-treated control group.
*** P < 0.001 compared with the ACSF-treated control group.
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Fig. 3. Effect of an EP1 or EP4 antagonist on the anxiolytic-like activity of the EP1 or
EP4 agonist, respectively. ONO-DI-004 (100 pmol/mouse, i.c.v.), an agonist for the
EP1 receptor, was co-administered with ONO-8713 (1 nmol/mouse), an antagonist
for the EP1 receptor, 20 min before the test (A–C). ONO-AE1-329 (100 pmol/mouse,
i.c.v.), an agonist for the EP4 receptor, was also co-administered ONO-AE3-208
(1 nmol/mouse), an antagonist for the EP4 receptor, 20 min before the test (D–F).
Each value is expressed as the mean ± S.E.M. (n = 4–5). ⁄P < 0.05, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001 compared with each group.
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Fig. 4. Involvement of both EP1 and EP4 receptors in the anxiolytic-like activity of
PGE2. PGE2 (100 pmol/mouse, i.c.v.) was co-administered with ONO-8713 (1 nmol/
mouse) or ONO-AE3-208 (1 nmol/mouse), an antagonist for the EP1 or EP4 receptor,
respectively, 20 min before the test. Each value is expressed as the mean ± S.E.M.
(n = 4–5). ⁄P < 0.05, ⁄⁄⁄P < 0.001, compared with each group.
C. Suzuki et al. / FEBS Letters 585 (2011) 2357–2362 2359results indicate that EP1 and EP4 agonists have anxiolytic-like
activity.
Next, we investigated whether the anxiolytic-like activity of
PGE2 was mediated by EP1 and EP4 receptors. The increase in time
and visits in open arms after the i.c.v. administration of the EP1 or
EP4 agonist (100 pmol/mouse) was inhibited by an EP1 or EP4
antagonist (1 nmol/mouse), respectively (Fig. 3). The EP1 or EP4
antagonist alone (1 nmol/mouse) was without effect under our
experimental condition. PGE2-induced anxiolytic-like activity was
also blocked by the EP1 or EP4 antagonist after a central adminis-
tration (Fig. 4). Thus we found that PGE2 exhibits anxiolytic-like
activity via EP1/EP4 receptors.
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shown to be selective across EP receptor subtypes, we sought to
conﬁrm the involvement of EP1/EP4 receptors in the anxiolytic-like
activity by using knockout mice deﬁcient in each EP subtype [9,14].
Genetic deletion of the EP4 receptor abolished the anxiolytic-like
activity of PGE2 (Fig. 5A). Thus we demonstrated that anxiolytic-
like action of PGE2 is mediated through the EP4 receptor. Whereas
the anxiolytic activity of PGE2 was spared in EP1-deﬁcient mice
(Fig. 5B), these mice failed to show the anxiolytic-like activity of
an EP1 agonist seen in wild-type mice (Fig. 5C). Thus, activation
of EP1 receptor can reduce the level of anxiety, though this receptor
is dispensable for the anxiolytic action of PGE2.
3.3. The anxiolytic-like activity of PGE2 is associated with the
activation of serotonin 5-HT1A, dopamine D1 and GABAA receptors
Next, we investigated mediators associated with the anxiolytic-
like activity of PGE2. Serotonin 5-HT1A, dopamine D1 and GABAA
receptors are known to be involved in anxiolytic-like activity in
animals and humans [21,23–25]; thus, we investigated whether
these receptors were involved in the anxiolytic-like activity of
PGE2 using antagonists for them.
The increase in % of time and visits in open arms after the cen-
tral administration of PGE2 (100 pmol/mouse, i.c.v.) was blocked
by WAY100135 (10 mg/kg, i.p.), a 5-HT1A receptor antagonist
(Fig. 6). We previously conﬁrmed that WAY100135 at this dose
by itself had no effect [21]. These results suggest that the anxio-
lytic-like activity of PGE2 is mediated by the activation of 5-HT1AA EP KO PGE
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Fig. 5. Anxiolytic-like activity of PGE2 or an EP1 agonist in the EP4- or EP1-KO mice.
The EP4-KO and wild-type mice were administered PGE2 (A, 10 pmol/mouse, i.c.v.)
20 min before the test. The EP1-KO and wild-type mice were also i.c.v. administered
PGE2 (B, 10 pmol/mouse) or ONO-DI-004, an EP1 agonist (C, 100 pmol/mouse)
20 min before the test. Each value is expressed as the mean ± S.E.M. (A: n = 5–7; B:
n = 3–10; C: n = 4–7). ⁄P < 0.05, ⁄⁄P < 0.01, compared with each group.
Fig. 6. Effect of an antagonist for the serotonin 5-HT1A, dopamine D1, GABAA
receptor on the anxiolytic-like activity of PGE2. WAY100135 (10 mg/kg) or
SCH23390 (30 lg/kg), an antagonist for the 5-HT1A or D1 receptor, respectively,
was administered i.p. 30 min before the EPM test (A–C). Bicuculline (5 mg/kg) or
ﬂumazenil (1 mg/kg), an antagonist for the GABA- or benzodiazepine-binding site
of the GABAA receptor, respectively, was administered i.p. 30 min before the EPM
test (D–F). PGE2 (100 pmol/mouse, i.c.v.) was administered 20 min before the test.
Each value is expressed as the mean ± S.E.M. (A–C: n = 4–6; D–F: n = 5–8). ⁄P < 0.05,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 compared with each group.receptors. The anxiolytic-like activity of PGE2 was also blocked
by SCH23390 (30 lg/kg, i.p.), a dopamine D1 receptor antagonist
(Fig. 6). Bicuculline (5 mg/kg, i.p.) and ﬂumazenil, antagonists for
the binding site of GABA and benzodiazepine, respectively, of the
GABAA receptor, also inhibited the anxiolytic-like activity induced
by the central administration of PGE2 (Fig. 6). When administered
alone these antagonists, including SCH23390, bicuculline and ﬂu-
mazenil, did not affect any parameters in the elevated plus-maze
test under our experimental conditions [21]. Taken together, the
anxiolytic-like activity of PGE2 is mediated by the activation of
serotonin 5-HT1A, dopamine D1 and GABAA receptors.
4. Discussion
We found that central administration of PGE2 exhibits anxio-
lytic-like activity in mice as measured by the elevated-plus maze
and open ﬁeld test. This action of PGE2 was abolished in mice trea-
ted with an EP4 antagonist and in EP4-KO mice. Further, central
administration of an EP4 agonist mimicked the action of PGE2.
These results demonstrate that central administration of PGE2
has anxiolytic-like activity via the EP4 receptor. We also found that
central activation of EP1 receptor has anxiolytic-like activity as
well. Consistently, an EP1 antagonist blocked the anxiolytic-like ef-
fect of PGE2, suggesting an involvement of the EP1 receptor in the
anxiolytic-like action of PGE2. However, genetic deletion of the EP1
receptor did not interfere with the action of PGE2. Thus, the EP4
receptor plays a dominant role in mediating the anxiolytic-like ac-
tion of PGE2, and EP1 deﬁciency in the long term could be compen-
sated by the remaining EP4 action.
C. Suzuki et al. / FEBS Letters 585 (2011) 2357–2362 2361PGE2 is a bioactive lipid produced from arachidonic acid, via
PGH2, by cyclooxygenase (COX), and acts on its receptors close to
its synthesis [6]. Under normal physiological conditions, brain-cell
population expressing either COX isoform constitutively, namely,
glial COX-1 and neuronal COX-2, might contribute to PGE2 produc-
tion [11,26]. Further investigation will elucidate how PGE2 is re-
leased in response to various stresses including psychological
stress not related to sickness. The EP1 and EP4 receptors are present
in areas such as the paraventricular nucleus of the hypothalamus
(PVN) and the amygdala [9,11,27].
Acute infections and other immune changes trigger acute phase
reactions including a variety of central responses such as fever, an-
orexia, HPA axis activation, reduced social interaction and explora-
tion behavior, namely, sickness behavior [28]. Pro-inﬂammatory
cytokines released by activation of the innate immune system
are known to induce expression of COX-2 and microsomal PGE
synthase (mPGES)-1 in the brain microvessels, and PGE2 might
be released and distributed to the large brain area [11]. In the
PVN, an important site in the HPA axis, expression of COX-2 and
EP4 is particularly induced by LPS administration [9,27]. The sick-
ness behavior is thought to be at least in part associated with the
cytokines, including interleukin-1b (IL-1b) and tumor necrosis fac-
tor (TNF)-a [29,30]. Corticotropin-releasing factor (CRF), which is
release from the PVN via PGE2 synthesis upon treatment with
LPS and IL-1b, was shown to increase anxiety behavior after central
administration [31]. In contrast, we found that PGE2 decreases anx-
iety via EP1/EP4 receptors. Thus, we hypothesize that the central
PGE2 system might suppress excessive anxiety-like behavior dur-
ing sickness. Complement C3a after central administration also in-
duced anxiolytic-like activity, and the anxiolytic-like activity of
C3a was blocked by a COX inhibitor and an EP1/EP4 antagonist
(unpublished data), suggesting that central C3a exhibits anxio-
lytic-like activity through PGE2 production followed by activation
of EP1/EP4 receptors. Further investigation should reveal the roles
of the novel anxiolytic pathway through PGE2–EP1/EP4 receptor
under physiological and pathophysiological conditions.
We also investigated the mechanism underlying the anxiolytic-
like activity of PGE2, downstream of EP1/EP4 receptor. The anxio-
lytic-like activity of PGE2 was completely blocked by antagonists
for 5-HT1A, D1 and GABAA receptors; however, each antagonist by
itself has no effect under our experimental condition. These results
suggest that the PGE2-induced anxiolytic-like activity is mediated
by activation of their receptors. By pharmacological experiments
using agonists and antagonists, we previously determined that
the order of activation was 5-HT1A, D1 and GABAA receptors [21].
Thus, we also hypothesized that the anxiolytic-like activity of
PGE2 was mediated as follows: EP1/EP4 receptor activation? sero-
tonin release? 5-HT1A receptor? dopamine release? D1 recep-
tor? GABA release? GABAA receptor? anxiolytic-like activity;
however, it cannot be ruled out that 5-HT1A, D1 and GABAA systems
might be activated in parallel after central administration of PGE2.
The serotonin–5-HT1A system is involved in the anxiolytic activ-
ity [32–35]. Serotonin neurons project to broad area such as the
PVN and central nucleus of the amygdala (CeA), in which the
EP1/EP4 receptors are present [9,11,27,36]. In the dorsal raphe nu-
cleus (DR), the most prominent serotonin source, EP4 receptor
was also reported to exist [27]. PGE2 administration into the DR
suppressed food intake, and LPS-induced anorexia was blocked by
injection of a COX-2 inhibitor NS-398 into the DR [36], implying
that PGE2 released in response to LPS acts on serotonergic neurons.
5-HT1A receptors are located not only in the serotonergic cell bodies
of the DR but also in non-serotonergic neurons in various brain re-
gions, including the hippocampus, prefrontal cortex and ventral
tegmental area (VTA) [37]. The mesocorticolimbic pathway with
dopaminergic projections from the VTA to frontal cortex and/or nu-
cleus accumbens is implicated in emotional and cognitiveregulation, and the nigrostriatal pathway from the substantia nigra
to the striatum is involved in motor function [38]. Systemic admin-
istration of a 5-HT1A agonist facilitated dopamine release in the
frontal cortex or nucleus accumbens [37]. The anxiolytic-like activ-
ity of PGE2 was blocked by bicuculline, an antagonist of the GABA
binding site of the GABAA receptor, suggesting that PGE2 might
show an anxiolytic-like effect after activating the GABA site, prob-
ably by stimulating presynaptic GABA release. Further investigation
should reveal the functional or structural relevance of 5-HT1A, D1
and GABAA receptors in anxiolytic-like activity of PGE2.
PGE2 is produced from arachidonic acid by COX followed by PGE
synthase. We also found that another COX product, PGD2, also has
anxiolytic-likeactivityvia theDP1 receptor amongtworeceptor sub-
types for PGD2 [12]. This anxiolytic-like activity was mediated by
activating the adenosine A2A and GABAA receptors, which is consis-
tentwith thepathwayof sleep induction. The anxiolytic-like activity
of PGE2 was not blocked by an A2A receptor antagonist (data not
shown), whereas the PGD2-induced anxiolytic-like activity was not
inhibited by a 5-HT1A receptor antagonist [12], indicating that
PGE2 and PGD2 exhibit anxiolytic-like activities via independent
pathways in the CNS; however, the GABAA receptor might be com-
monly involved downstream of all other neurotransmitters.
Among a number of bioactive peptides isolated from the
enzymatic digests of food proteins, several short peptides exhib-
ited anxiolytic-like activity. Soymorphin-5 and rubiscolin-6, which
are l and d opioid peptides derived from soy b-conglycinin and
spinach Rubisco, respectively, have anxiolytic-like activities after
oral administration [18,19]. Rubiscolin-6 exhibits anxiolytic activ-
ity by activating r1 receptor, downstream of d opioid receptor
[19]; however, PGE2-induced anxiolytic-like activity was not
blocked by antagonists for l and d opioid receptors, naloxone
and naltrindole and BMY14802, respectively (data not shown),
suggesting that PGE2 shows anxiolytic-like activity independently
of these opioid systems. It was also reported that rubimetide, a tri-
peptide derived from Rubisco, a tripeptide exhibits anxiolytic-like
activities via activation of the PGD2 system [20]. It is worthwhile
testing the anxiolytic-like activities of PG-releasing peptides de-
rived from dietary proteins.
In conclusion, we found that centrally administered PGE2
exhibited anxiolytic-like activity in mice. We also demonstrated
that the anxiolytic-like activity of PGE2 is mediated by the EP1/
EP4 receptors using selective ligands. Since genetic deletion of
the EP4 rather than the EP1 receptor abolished the anxiolytic ef-
fect of PGE2, the EP4 receptor must play a dominant role in this
PGE2 action. The PGE2-induced anxiolytic-like activity was medi-
ated via serotonin 5-HT1A, dopamine D1 and GABAA receptors. Ta-
ken together, activation of central EP4 receptors for PGE2 exhibits
anxiolytic-like activity, dependent on the 5-HT1A, D1 and GABAA
receptors system.Acknowledgment
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